SVA: Sinovac Biotech Ltd insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Clinical trial readouts
8 Phase 2 or 3 trials by Sinovac Biotech Ltd with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2026-09-30 (est.) | Sinovac rabies vaccine | Rabies (Healthy Volunteers) | Phase 3 | 912 | Not yet recruiting | NCT07416110 |
| 2026-11 (est.) | experimental vaccine | Epidemic Meningitis | Phase 3 | 660 | Enrollment complete | NCT07505888 |
| 2026-12-30 (est.) | Rabies Vaccine (Serum-free Vero Cell), Freeze-dried | Rabies | Phase 3 | 390 | Not yet recruiting | NCT07055295 |
| 2027-01 (est.) | experimental vaccine | Epidemic Meningitis | Phase 3 | 1,040 | Recruiting | NCT07505836 |
| 2027-01-30 (est.) | Rabies vaccine | Rabies (Healthy Volunteers) | Phase 3 | 390 | Not yet recruiting | NCT07055893 |
| 2027-04 (est.) | experimental vaccine | Epidemic Meningitis | Phase 3 | 1,040 | Recruiting | NCT07505823 |
| 2027-04 (est.) | experimental vaccine | Epidemic Meningitis | Phase 3 | 880 | Recruiting | NCT07505810 |
| 2027-09-15 (est.) | Inactivated Hepatitis A Vaccine (Human Diploid Cell) (1 mL) | Hepatitis A Vaccine | Phase 3 | 680 | Recruiting | NCT07793227 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.